Leopold SCHMETTERER (Austria)

Leopold Schmetterer, PhD, FARVO, is currently the chair of the Ophthalmic Pharmacology Division in the Department of Clinical Pharmacology and a principal investigator at the Center of Medical Physics and Biomedical Engineering at the Medical University of Vienna.

His research interests include a wide array of subspecialties in ophthalmology, including imaging, glaucoma, medical retina and dry eye syndrome. Dr. Schmetterer was recently responsible for the MANTA study, a multicenter study in Austria that compared the effects of ranibizumab and bevacizumab for the treatment of neovascular age-related macular degeneration.

He graduated from the Technical University of Vienna in 1989. Between 1996 and 1998, Dr. Schmetterer held a postdoctoral position at the Institute de Recherche en Ophthalmologie in Sion working with Dr. Charles Riva. He was a guest professor at EPFL in Lausanne between 1998 and 2002. Dr. Schmetterer has experience in organizing scientific conferences for several associations. He served on the PH Section of the Annual Meeting Program Committee for ARVO between 2009 and 2011 and became an ARVO Silver Fellow at the 2014 annual meeting in Orlando. In 2012, he was president of European Vision and Eye Research (EVER), the largest European ophthalmological research conference. He was elected president of the EVER Foundation in 2013 for a four-year period. He is also involved in the International Symposium on Ocular Pharmacology and Therapeutics (program committee member since 2009) and the World Ophthalmology Congress (program committee member for the 2014 meeting in Tokyo). He is also on the Scientific Committee of the Austrian Ophthalmological Society, president of the Association of Ocular Circulation, representative of medicine in the council of the Austrian Science Fund and a founding member of the European Alliance for Vision Research and Ophthalmology. He was a member of the European Medical Research Council from 2010 to 2012.

Dr. Schmetterer is a member of many editorial boards, including Progress of Retinal and Eye Research, Acta Ophthalmologica, Current Eye Research, Journal of Ocular Pharmacology and Therapeutics and Ophthalmic Research. He has published more than 250 articles in peer-reviewed journals and more than 50 book chapters. He recently edited a book on ocular blood flow. Dr. Schmetterer has received continuous funding from national and international sources for more than 15 years for a total of €5 million. He was recently appointed director of Christian Doppler Laboratory for Ocular Effects of Thiomers, a joint program between industrial and academic institutions.